Total debt jumped from $40.2M to $501.0M in a single quarter while equity turned negative at -$60.0M, leaving debt-to-equity not meaningful and the current ratio compressed to 0.61 from 2.08 despite $305.0M in cash.
Supernus Pharmaceuticals, Inc. (SUPN) balance sheet — 18-year assets, liabilities & shareholders' equity history
| Metric | TTM | Dec'25 | Dec'24 | Dec'23 | Dec'22 | Dec'21 | Dec'20 | Dec'19 | Dec'18 | Dec'17 | Dec'16 | Dec'15 | Dec'14 | Dec'13 | Dec'12 | Dec'11 | Dec'10 | Dec'09 | Dec'08 |
|---|
| Total Current Assets | 800M | 652M | 839M | 1.27B | 1.27B | 1.44B | 1.19B | 1.36B | 1.33B | 1.22B | 990M | 105.98M | 108.89M | 97.16M | 91.74M | 49.4M | 39.81M | 72.88M | 69.46M |
| Cash & Short-Term Investments | 305M | 195M | 320M | 410M | 897.83M | 1.1B | 858M | 1.06B | 924M | 863M | 692M | 62.19M | 74.34M | 82.19M | 88.51M | 48.54M | 32.7M | 66.52M | 60.38M |
| Cash Only | 305M | 195M | 319M | 316M | 778.18M | 1.1B | 858M | 1.06B | 924M | 863M | 692M | 62.19M | 74.34M | 82.19M | 88.51M | 48.54M | 23.74M | 31.41M | 52.88M |
| Short-Term Investments | 0 | 0 | 1M | 94M | 119.64M | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 8.96M | 35.12M | 7.5M |
| Accounts Receivable | 286M | 255M | 254M | 254M | 220M | 202M | 219M | 204M | 278M | 257M | 205M | 25.91M | 17.27M | 5.05M | 675K | 0 | 158K | 3.74M | 2.28M |
| Days Sales Outstanding | 73.92 | 75.12 | 78.04 | 84.82 | 89.12 | 93.21 | 123.55 | 94.85 | 105.71 | 81.7 | 77.23 | 65.48 | 51.65 | 153.48 | 166.47 | - | 544.06 | 36.01 | 93.47 |
| Inventory | 149M | 153M | 178M | 135M | 114.62M | 95M | 93M | 73M | 78M | 52M | 41M | 12.59M | 13.44M | 7.15M | 1.15M | 389K | 6.75M | 2.35M | 6.55M |
| Days Inventory Outstanding | 270.17 | 227.01 | 281.26 | 283.19 | 277.05 | 273.03 | 349.95 | 190.32 | 211.4 | 154.44 | 135.05 | 545.44 | 852.03 | 2.36K | - | - | -183.94 | -99.75 | 1000K |
| Other Current Assets | 39M | 15M | 34M | 444M | 18M | 27M | 0 | 0 | 49M | 38M | 40M | 0 | 3.85M | 0 | 144K | 0 | 6.75M | 0 | 0 |
| Total Non-Current Assets | 532M | 552M | 481M | 499M | 512.76M | 388M | 344M | 292M | 218M | 219M | 219M | 82.75M | 28.62M | 13.83M | 2.25M | 4.33M | 7.2M | 7.02M | 7.68M |
| Property, Plant & Equipment | 187M | 170M | 139M | 124M | 85.46M | 95M | 103M | 107M | 57M | 54M | 27M | 3.87M | 2.45M | 2.55M | 1.42M | 1.31M | 1.25M | 1.86M | 1.99M |
| Fixed Asset Turnover | 7.64x | 7.29x | 8.55x | 8.81x | 10.54x | 8.33x | 6.28x | 7.34x | 16.84x | 21.26x | 35.88x | 37.28x | 49.85x | 4.71x | 1.04x | 0.61x | 0.08x | 20.40x | 4.47x |
| Goodwill | 0 | 0 | 2M | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 2M | 2M | 5M | 13M | 70M | 82M | 62M | 72M | 0 | 0 | 0 | 976K | 5.43M | 1.16M | 683K | 912K | 1.14M | 1.37M | 1.6M |
| Long-Term Investments | 109M | 28M | 26M | 41M | 98.53M | 0 | 0 | 0 | 33M | 15M | 0 | 55.01M | 19.82M | 8.76M | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Assets | 28M | 26M | 29M | 28M | 38.58M | 106M | 104M | 73M | 84M | 92M | 83M | 391K | 6.35M | 1.52M | 144K | 2.11M | 4.8M | 3.79M | 4.09M |
| Total Assets | 1.33B | 1.2B | 1.32B | 1.76B | 1.78B | 1.83B | 1.53B | 1.65B | 1.55B | 1.44B | 1.21B | 188.73M | 137.51M | 111M | 93.99M | 53.73M | 47.01M | 79.9M | 77.13M |
| Asset Turnover | 1.11x | 1.03x | 0.90x | 0.62x | 0.51x | 0.43x | 0.42x | 0.48x | 0.62x | 0.80x | 0.80x | 0.77x | 0.89x | 0.11x | 0.02x | 0.01x | 0.00x | 0.47x | 0.12x |
| Asset Growth % | -42.68% | -8.72% | -25.27% | -0.76% | -2.92% | 19.66% | -7.32% | 6.79% | 7.13% | 19.44% | 540.6% | 37.25% | 23.89% | 18.09% | 74.93% | 14.3% | -41.16% | 3.58% | - |
| Total Current Liabilities | 1.3B | 914M | 939M | 1.29B | 1.02B | 804M | 599M | 742M | 818M | 854M | 1.03B | 56.1M | 27.49M | 26.4M | 22.98M | 18.77M | 15.21M | 10.03M | 8.27M |
| Accounts Payable | 28M | 48M | 63M | 39M | 33M | 26M | 416M | 499M | 47M | 40M | 33M | 4.31M | 1.86M | 3.14M | 2.81M | 10.08M | 11.26M | 6.25M | 4.47M |
| Days Payables Outstanding | 63.07 | 71.22 | 99.55 | 81.81 | 79.77 | 74.72 | 1.57K | 1.3K | 127.38 | 118.8 | 108.7 | 186.94 | 118.1 | 1.04K | - | - | -306.7 | -265.42 | 1000K |
| Short-Term Debt | 488M | 39M | 18M | 12M | 3M | 3M | 12M | 9M | 4M | 5M | 101M | 497K | 0 | 0 | 11.81M | 6.78M | 0 | 0 | 0 |
| Deferred Revenue (Current) | 0 | 0 | 0 | 0 | 9.05M | 0 | 0 | 0 | 24M | 41M | 52M | 176K | 143K | 8.09M | 508K | 232K | 0 | 0 | 0 |
| Other Current Liabilities | 77M | 722M | 802M | 1.16B | 391M | 635M | 156M | 195M | 603M | 617M | 673M | 26.79M | 19.7M | 10.16M | 7.86M | 1.55M | 2.5M | 1.29M | 2.5M |
| Current Ratio | 0.61x | 0.71x | 0.89x | 0.98x | 1.24x | 1.80x | 1.98x | 1.83x | 1.62x | 1.43x | 0.96x | 1.89x | 3.96x | 3.68x | 3.99x | 2.63x | 2.62x | 7.26x | 8.39x |
| Quick Ratio | 0.50x | 0.55x | 0.70x | 0.88x | 1.12x | 1.68x | 1.83x | 1.73x | 1.53x | 1.37x | 0.92x | 1.66x | 3.47x | 3.41x | 3.94x | 2.61x | 2.17x | 7.03x | 7.60x |
| Cash Conversion Cycle | 281.02 | 230.91 | 259.75 | 286.2 | 286.41 | 291.52 | -1.09K | -1.02K | 189.72 | 117.34 | 103.58 | 423.98 | 785.58 | 1.48K | - | - | 666.81 | 201.68 | 1000K |
| Total Non-Current Liabilities | 91M | 388M | 728M | 666M | 702.78M | 825M | 850M | 701M | 663M | 793M | 474M | 13.76M | 38.66M | 51.13M | 13.44M | 25.52M | 76.12M | 76.02M | 75.61M |
| Long-Term Debt | 0 | 290M | 315M | 237M | 237M | 239M | 230M | 233M | 237M | 477M | 434M | 7.08M | 26.95M | 34.39M | 11.09M | 22.71M | 75M | 75M | 75M |
| Capital Lease Obligations | 55M | 22M | 32M | 34M | 29M | 36M | 43M | 51M | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -942K | 0 | 0 | 0 |
| Deferred Tax Liabilities | 3M | 3M | 0 | 5M | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 854K | 6.56M | 12.64M | -309K | 942K | 0 | 0 | -75M |
| Other Non-Current Liabilities | 85M | 73M | 381M | 390M | 436.78M | 550M | 577M | 417M | 426M | 316M | 40M | 35.21M | 10.44M | 15.32M | 2.04M | 1.4M | 1.12M | 1.02M | 169.62K |
| Total Liabilities | 1.39B | 1.3B | 1.67B | 1.96B | 1.73B | 1.63B | 1.45B | 1.44B | 1.48B | 1.65B | 1.5B | 69.86M | 66.15M | 77.53M | 36.42M | 44.29M | 91.33M | 86.06M | 83.88M |
| Total Debt | 501M | 351M | 375M | 283M | 277M | 286M | 285M | 293M | 241M | 482M | 535M | 7.19M | 26.95M | 34.39M | 22.9M | 29.49M | 75M | 75M | 75M |
| Net Debt | 196M | 156M | 56M | -33M | -501.18M | -816M | -573M | -767M | -683M | -381M | -157M | -55M | -47.39M | -47.8M | -65.61M | -19.06M | 51.26M | 43.59M | 22.12M |
| Debt / Equity | -8.35x | - | - | - | 5.40x | 1.41x | 3.48x | 1.40x | 3.65x | - | - | 0.06x | 0.38x | 1.03x | 0.40x | 3.12x | - | - | - |
| Debt / EBITDA | 0.82x | 1.23x | 6.25x | - | - | 1.22x | - | 1.42x | 0.72x | 1.10x | 1.52x | 0.39x | 1.07x | - | - | - | - | 14.74x | - |
| Net Debt / EBITDA | 0.32x | 0.55x | 0.93x | - | - | -3.47x | - | -3.72x | -2.05x | -0.87x | -0.45x | -2.96x | -1.88x | - | - | - | - | 8.57x | - |
| Interest Coverage | 32.65x | 6.31x | 1.34x | -3.26x | -2.14x | 8.31x | -6.21x | 9.18x | 9.52x | 3.94x | 2.68x | 4.37x | 4.42x | -10.76x | -11.95x | -20.15x | - | - | -2.86x |
| Total Equity | -60M | -98M | -348M | -191M | 51.28M | 203M | 82M | 209M | 66M | -203M | -295M | 118.88M | 71.35M | 33.46M | 57.57M | 9.44M | -44.32M | -6.16M | -6.75M |
| Equity Growth % | 211.88% | 71.84% | -82.2% | -472.5% | -74.74% | 147.56% | -60.77% | 216.67% | 132.51% | 31.19% | -348.16% | 66.6% | 113.23% | -41.87% | 509.66% | 121.31% | -619.95% | 8.76% | - |
| Book Value per Share | -0.49 | -0.77 | -2.62 | -1.35 | 0.37 | 1.32 | 0.56 | 1.38 | 0.44 | -1.36 | -1.98 | 2.32 | 1.41 | 1.05 | 3.30 | 0.68 | -3.20 | -0.44 | -0.49 |
| Total Shareholders' Equity | -60M | -98M | -348M | -191M | 51.28M | 203M | 82M | 209M | 66M | -203M | -295M | 118.88M | 71.35M | 33.46M | 57.57M | 9.44M | -44.32M | -6.16M | -6.75M |
| Common Stock | 0 | 62M | 62M | 68M | 68.37M | 70M | 73M | 73M | 73M | 72M | 72M | 49K | 43K | 40K | 31K | 14K | 2K | 6K | 5.52K |
| Retained Earnings | -197M | -243M | -454M | -295M | 1.31B | 1.44B | 1.31B | 1.45B | 1.31B | 1.03B | 950M | -144.64M | -158.66M | -178.53M | -86.25M | -39.97M | -93.79M | -55.32M | -55.78M |
| Treasury Stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Accumulated OCI | -26M | -30M | -46M | -1.35B | -1.34B | 0 | -1.31B | -1.32B | -1.33B | -1.31B | -1.32B | -488K | -154K | 0 | -57K | 1K | 0 | 2K | -2.15M |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Quick answers to the most common questions about buying SUPN stock.
As of 2025, Supernus Pharmaceuticals, Inc. (SUPN) had total assets of $1.20B including $652.0M in current assets.
Supernus Pharmaceuticals, Inc. (SUPN) carries total debt of $351.0M, offset by $195.0M in cash and short-term investments. Comparing total debt to cash helps evaluate the company's debt burden and net leverage.
Supernus Pharmaceuticals, Inc. (SUPN) has total shareholders' equity (book value) of $-98.0M ($-0.77 book value per share). Book value represents the net worth of the company belonging to common stock holders.
Supernus Pharmaceuticals, Inc. (SUPN) reported a current ratio of 0.71x. A current ratio above 1.0x indicates that the company has more current assets than current liabilities, suggesting sufficient short-term liquidity.
Key Metrics
Top Statement Risk
Negative equity after acquisition outflow
Metrics are mathematically derived from official filings.
Equity Swings Negative After Acquisition Spending
According to the supplied balance sheet, SUPN's equity fell from roughly $1.0B in 2026Q2 to -$60.0M in 2026Q3 while total liabilities rose to $1.4B, a shift that appears driven by the large acquisition-related outflow and debt build.
The reported figures suggest the balance sheet weakened sharply in the latest quarter rather than gradually, with total debt climbing from $40.2M to $501.0M alongside a drop in retained earnings from $457.2M to -$197.0M. This pattern indicates the recent acquisition was funded largely with borrowing and reserves, which may limit financial flexibility until the acquired assets are shown to generate durable earnings. Investors should monitor whether the negative equity position persists and how quickly the debt load is serviced.
Leverage Jumps From Minimal to Material
Based on reported figures, SUPN's total debt rose from $40.2M to $501.0M in one quarter, lifting debt-to-equity from 0.04 to a negative ratio that is not meaningful under negative book equity.
Prior to 2026Q3 the company carried very low leverage, so the jump appears strategic in nature, tied to the acquisition rather than operating needs. The negative equity makes conventional leverage ratios unreliable, so the more relevant measure is debt relative to cash of $305.0M, which suggests net debt of roughly $196M. Refinancing terms and the timing of repayment warrant further investigation, as the reported data does not disclose maturity schedules.
Goodwill Largely Absent Despite Acquisition
As reported in the balance sheet, SUPN's goodwill was $119.4M in 2026Q2 but only $2.0M in 2026Q3, while total assets remained near $1.3B to $1.4B, which raises questions about how acquired value was classified.
The sharp decline in goodwill alongside a large asset base suggests the acquisition may have been recorded primarily as identifiable intangibles or other assets rather than goodwill, though the supplied data does not confirm this allocation. The PPE base of $187.0M in the latest quarter versus $35.6M prior also points to a material asset addition that may warrant closer review. The asset mix shift implies a more asset-heavy profile than the company historically carried.
Current Ratio Compresses With Rising Obligations
According to the reported figures, SUPN's current ratio declined from 2.08 in 2026Q2 to 0.61 in 2026Q3, while cash of $305.0M provides a partial buffer against the increase in current obligations.
A current ratio below 1.0 indicates current liabilities now exceed current assets, a meaningful change from the prior comfortable level near 2.0. Cash has also risen from $180.0M to $305.0M, which appears to offset some of this pressure, but the reported data does not break out the maturity profile of liabilities. Liquidity should be assessed in conjunction with cash flow durability, which has been volatile across recent quarters.
Negative Equity Masks Underlying Cash Position
The most misleading headline is the negative book equity of -$60.0M, which may overstate balance sheet distress given $305.0M in cash, yet it may also signal that prior accumulated earnings were largely consumed by the acquisition.
Because retained earnings swung from $457.2M to -$197.0M in one quarter, the equity figure appears driven by a large charge or distribution rather than ongoing operating losses, a distinction the supplied data alone cannot confirm. Headline leverage and equity metrics therefore may not reflect the company's true capacity to service debt. Investors should monitor whether future cash flow, rather than book equity, supports the balance sheet going forward.